OTCPK:DVXI.F

Stock Analysis Report

Executive Summary

DVx Inc. engages in the import/export of medical devices and related peripheral devices in Japan.

Snowflake

Fundamentals

Excellent balance sheet and fair value.

Risks

  • DVx is not covered by any analysts.

Share Price & News

How has DVx's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:DVXI.F

0.6%

US Healthcare

1.1%

US Market


1 Year Return

n/a

OTCPK:DVXI.F

-7.7%

US Healthcare

2.1%

US Market


Share holder returns

DVXI.FIndustryMarket
7 Day0%0.6%1.1%
30 Day0%-0.9%3.7%
90 Dayn/a0.02%2.3%
1 Yearn/a-6.3%-7.7%4.4%2.1%
3 Yearn/a31.5%26.2%47.0%37.4%
5 Yearn/a65.6%55.8%61.6%43.8%

Price Volatility Vs. Market

How volatile is DVx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is DVx undervalued based on future cash flows and its price relative to the stock market?

27%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

DVx's share price is below the future cash flow value, and at a moderate discount (> 20%).

DVx's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

DVx is good value based on earnings compared to the US Healthcare industry average.

DVx is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for DVx, we can't assess if its growth is good value.


Price Based on Value of Assets

DVx is good value based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is DVx expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

16.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if DVx is high growth as no revenue estimate data is available.

DVx's earnings are expected to grow by 16.8% yearly, however this is not considered high growth (20% yearly).

Unable to compare DVx's revenue growth to the United States of America market average as no estimate data is available.

DVx's earnings growth is expected to exceed the United States of America market average.

DVx's earnings growth is expected to exceed the low risk savings rate of 3%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if DVx will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has DVx performed over the past 5 years?

4.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

DVx's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.

DVx's 1-year earnings growth is negative, it can't be compared to the 5-year average.

DVx's 1-year earnings growth is negative, it can't be compared to the US Healthcare industry average.


Return on Equity

DVx has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

DVx used its assets less efficiently than the US Healthcare industry average last year based on Return on Assets.


Return on Capital Employed

DVx's use of capital has not improved over the past 3 years (Return on Capital Employed).


Next Steps

Financial Health

How is DVx's financial position?


Financial Position Analysis

DVx is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

DVx's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

DVx's level of debt (1.7%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (4.2% vs 1.7% today).

Debt is well covered by operating cash flow (941.4%, greater than 20% of total debt).

Unable to confirm if the interest payments on DVx's debt are well covered by earnings due to lack of past financial data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 135.7x debt.


Next Steps

Dividend

What is DVx's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate DVx's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate DVx's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as DVx has not reported any payouts.

Unable to verify if DVx's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as DVx has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of DVx's salary, the management and board of directors tenure and is there insider trading?

5.3yrs

Average board tenure


CEO

Shigeru Chiba (60yo)

0yrs

Tenure

0

Mr. Shigeru Chiba serves as President at DVx Inc. Mr. Chiba served as General Manager of Bitatron Asia Pacific at Medtronic (U.S.A.) since May 1999. Mr. Chiba has been Vice President of DVx Inc. since J ...


Board Age and Tenure

5.3yrs

Average Tenure

62yo

Average Age

The tenure for the DVx board of directors is about average.


Insider Trading

No 3 month insider trading information.


Ownership Breakdown


Management Team

  • Makoto Wakabayashi (68yo)

    Founder and Chairman of the Board

    • Tenure: 0yrs
  • Hiroshi Shibasaki (53yo)

    Executive VP & Director

    • Tenure: 8.3yrs
  • Masayuki Nabeya (60yo)

    Executive Officer and Director

    • Tenure: 7.3yrs
  • Hiroki Matsumoto

    Executive Officer

    • Tenure: 0yrs
  • Toshihiko Azuma

    Executive Officer

    • Tenure: 0yrs
  • Kazuyuki Nakano

    Executive Officer and Manager of 1st Sales Department

    • Tenure: 0yrs
  • Naohiro Hirano

    Executive Officer and Director

    • Tenure: 3.3yrs
  • Shigeru Chiba (60yo)

    President and Representative Director

    • Tenure: 0yrs
  • Hideki Nakai

    Executive Officer

    • Tenure: 0yrs

Board Members

  • Akio Minawa (74yo)

    Outside Audit & Supervisory Board Member

    • Tenure: 12.6yrs
  • Makoto Wakabayashi (68yo)

    Founder and Chairman of the Board

    • Tenure: 0yrs
  • Sachiko Toda (62yo)

    Audit & Supervisory Board Member

    • Tenure: 4.3yrs
  • Mitsuharu Muramatsu (65yo)

    Outside Director

    • Tenure: 11.3yrs
  • Hiroshi Shibasaki (53yo)

    Executive VP & Director

    • Tenure: 8.3yrs
  • Masayuki Nabeya (60yo)

    Executive Officer and Director

    • Tenure: 7.3yrs
  • Naohiro Hirano

    Executive Officer and Director

    • Tenure: 3.3yrs
  • Shigeru Chiba (60yo)

    President and Representative Director

    • Tenure: 0yrs
  • Shigeharu Dogakinai

    Outside Director

    • Tenure: 3.3yrs
  • Satoshi Miyamoto

    Director

    • Tenure: 0.8yrs

Company Information

DVx Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: DVx Inc.
  • Ticker: DVXI.F
  • Exchange: OTCPK
  • Founded: 1986
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: JP¥15.078b
  • Listing Market Cap: JP¥134.384m
  • Shares outstanding: 11.28m
  • Website: https://www.dvx.jp

Number of Employees


Location

  • DVx Inc.
  • Mejiro Nakano Building
  • 5th Floor
  • Tokyo
  • 171-0033
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
3079TSE (The Tokyo Stock Exchange)YesCommon StockJPJPYApr 2007
DVXI.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDApr 2007

Biography

DVx Inc. engages in the import/export of medical devices and related peripheral devices in Japan. The company sells arrhythmia-related products, such as cardiac pacemakers, implantable cardioverter defibri ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2018/10/23 21:35
End of Day Share Price2018/07/26 00:00
Earnings2018/06/30
Annual Earnings2018/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.